Theravance cuts 17% of staff, JAK inhibitor program
Theravance Biopharma is cutting 17% of its workforce and a mid-stage inhaled JAK inhibitor program, it announced Monday afternoon.
Theravance will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
